(RTTNews) - BriaCell Therapeutics Corp. (BCTX) rose 4.16% to trade at $12.77, up $0.51, following news of a collaboration with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator and the expansion of its Phase 3 pivotal study (NCT06072612).
The partnership supports Bria-OTS+™ and Bria-BRES+™ programs through manufacturing, IND preparation, and clinical protocol development. The Phase 3 trial now includes three additional U.S. cancer centers, Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University, bringing the total to 79 sites across 23 states, with top-line results expected in H1 2026.
On Tuesday, BCTX opened at $12.42, hit a high of $12.96, and a low of $12.42, compared to a previous close of $12.26 on the NASDAQ. Trading volume reached above average levels. The stock's 52-week range is $0.84 - $13.38.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
